Northern Trust Corp Viking Therapeutics, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 481,113 shares of VKTX stock, worth $22.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

481,113

Previous 916,466 47.5%

Holding current value

$22.7 Million

Previous $48.6 Million 37.3%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$49.84 - $70.47 $21.7 Million - $30.7 Million	-435,353 Reduced 47.5%	481,113 $30.5 Million
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $1.72 Million - $2.92 Million	-36,391 Reduced 3.82%	916,466 $48.6 Million
Q1 2024 May 14, 2024	BUY	$17.4 - $94.5 $634,699 - $3.45 Million	36,477 Added 3.98%	952,857 $78.1 Million
Q4 2023 Feb 13, 2024	SELL	$9.24 - $19.64 $103,321 - $219,614	-11,182 Reduced 1.21%	916,380 $17.1 Million
Q3 2023 Nov 13, 2023	BUY	$10.92 - $16.0 $173,344 - $253,984	15,874 Added 1.74%	927,562 $10.3 Million
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $11 Million - $18.3 Million	739,868 Added 430.61%	911,688 $14.8 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $363,907 - $780,508	45,038 Added 35.52%	171,820 $2.86 Million
Q4 2022 Feb 13, 2023	SELL	$2.72 - $9.4 $38 - $131	-14 Reduced 0.01%	126,782 $1.19 Million
Q2 2022 Aug 12, 2022	SELL	$2.11 - $3.15 $1.1 Million - $1.64 Million	-522,075 Reduced 80.46%	126,796 $366,000
Q1 2022 May 13, 2022	SELL	$3.0 - $4.88 $626,709 - $1.02 Million	-208,903 Reduced 24.35%	648,871 $1.95 Million
Q4 2021 Feb 08, 2022	SELL	$4.6 - $6.72 $532,371 - $777,725	-115,733 Reduced 11.89%	857,774 $3.95 Million
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $146,720 - $185,109	-26,294 Reduced 2.63%	973,507 $6.11 Million
Q2 2021 Aug 13, 2021	SELL	$5.19 - $6.73 $5,413 - $7,019	-1,043 Reduced 0.1%	999,801 $5.99 Million
Q1 2021 May 12, 2021	SELL	$5.74 - $9.67 $2.01 Million - $3.38 Million	-349,322 Reduced 25.87%	1,000,844 $6.33 Million
Q4 2020 Feb 11, 2021	SELL	$5.3 - $6.71 $198,108 - $250,813	-37,379 Reduced 2.69%	1,350,166 $7.6 Million
Q3 2020 Nov 16, 2020	SELL	$5.73 - $8.11 $214,433 - $303,500	-37,423 Reduced 2.63%	1,387,545 $8.08 Million
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $2.72 Million - $5.05 Million	624,386 Added 77.99%	1,424,968 $10.3 Million
Q1 2020 May 14, 2020	SELL	$3.45 - $7.95 $57,970 - $133,583	-16,803 Reduced 2.06%	800,582 $3.75 Million
Q4 2019 Feb 14, 2020	SELL	$6.38 - $8.73 $74,748 - $102,280	-11,716 Reduced 1.41%	817,385 $6.56 Million
Q3 2019 Nov 13, 2019	BUY	$6.55 - $8.6 $394,539 - $518,021	60,235 Added 7.83%	829,101 $5.7 Million
Q2 2019 Aug 13, 2019	BUY	$7.67 - $10.63 $91,395 - $126,667	11,916 Added 1.57%	768,866 $6.38 Million
Q1 2019 May 13, 2019	BUY	$7.58 - $9.94 $212,179 - $278,240	27,992 Added 3.84%	756,950 $7.52 Million
Q4 2018 Feb 12, 2019	BUY	$7.16 - $16.21 $816,204 - $1.85 Million	113,995 Added 18.54%	728,958 $5.58 Million
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $1.18 Million - $2.4 Million	122,118 Added 24.78%	614,963 $10.7 Million
Q2 2018 Sep 18, 2018	BUY	$3.88 - $12.74 $87,517 - $287,363	22,556 Added 4.8%	492,845 $4.68 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $1.52 Million - $4.99 Million	391,336 Added 495.66%	470,289 $4.46 Million
Q1 2018 May 09, 2018	BUY	$4.11 - $6.93 $159,883 - $269,583	38,901 Added 97.13%	78,953 $345,000
Q4 2017 Feb 14, 2018	BUY	$1.74 - $4.34 $40,176 - $100,210	23,090 Added 136.13%	40,052 $163,000
Q3 2017 Nov 13, 2017	BUY	$0.94 - $1.91 $15,944 - $32,397	16,962	16,962 $32,000

Others Institutions Holding VKTX

# of Institutions

474

Shares Held

66.2M

Call Options Held

5.72M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.62B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Viking Therapeutics, Inc. Transaction History